SOTIO Biotech, Biocytogen Ink Research and License Agreement to Develop Next-Generation Antibody-Drug Conjugates
The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.
The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.